financetom
Business
financetom
/
Business
/
Venture Global beats second-quarter revenue estimates on higher LNG sales
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Venture Global beats second-quarter revenue estimates on higher LNG sales
Aug 12, 2025 3:48 AM

Aug 12 (Reuters) - Venture Global ( VG ) surpassed Wall

Street expectations for second-quarter revenue on Tuesday, as

the easing of new export permits for liquefied natural gas in

the U.S. helped improve sales.

Commercial activity in the sector picked up pace after

President Donald Trump lifted a moratorium on new LNG export

permits soon after taking office in January.

Venture Global ( VG ), the country's second-largest LNG exporter

behind Cheniere Energy, has been ramping up commercial

operations at its Plaquemines and Calcasieu Pass export

facilities, both located in Louisiana.

The company said it sold 329 trillion British Thermal Units

(TBtu) of LNG during the quarter, a 149% jump from the 132 TBt

units of the superchilled fuel it sold a year earlier.

It expects to export 227 to 240 cargos of LNG from the

Plaquemines project this year, compared with a prior forecast of

222 to 239 cargoes. The Calcasieu Pass project is expected to

export 144 to 149 cargos, compared with its previous forecast of

145 to 150 cargoes.

Venture Global ( VG ) became one of the most valuable U.S. LNG

companies when it listed in January, though its stock has fallen

more than 27% as the company grapples with higher project costs.

Its operating expenses rose to $2.06 billion during the

second quarter from $745 million a year earlier.

The Arlington, Virginia-based company reported revenue of

$3.1 billion for the three months ended June 30, compared with

analysts' expectations of $2.89 billion, according to data

compiled by LSEG.

(Reporting by Vallari Srivastava in Bengaluru; Editing by Anil

D'Silva)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alpha Edge Media Expands Crypto Intelligence News Offerings With Acquisition of 21bitcoin.xyz
Alpha Edge Media Expands Crypto Intelligence News Offerings With Acquisition of 21bitcoin.xyz
Oct 15, 2025
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Alpha Edge Media, Inc., a wholly owned subsidiary of Aether Holdings, Inc. ( ATHR ) (“Aether Holdings”), an emerging financial technology platform integrating AI-driven analytics and digital media, today announced the acquisition of 21Bitcoin.xyz, an AI-powered crypto news engine delivering real-time coverage across the global digital asset ecosystem. Alpha Edge Media is...
Hillenbrand to be acquired by investment firm Lone Star for $3.8 billion
Hillenbrand to be acquired by investment firm Lone Star for $3.8 billion
Oct 15, 2025
Oct 15 (Reuters) - Hillenbrand ( HI ) said on Wednesday it will be acquired by investment firm Lone Star in an all-cash deal with an enterprise value of about $3.8 billion, sending the industrial equipment maker's shares up more than 18% in premarket trading. An affiliate of Lone Star will pay $32 a share, and the deal is expected...
Roundtable CEO James Heckman and RYVYL Announce NASDAQ Listing Secured, with Direct Equity Investment and Reverse Split Ahead of Merger
Roundtable CEO James Heckman and RYVYL Announce NASDAQ Listing Secured, with Direct Equity Investment and Reverse Split Ahead of Merger
Oct 15, 2025
SAN DIEGO, CA, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Roundtable CEO James Heckman and RYVYL Inc. ( RVYL ) today announced that RYVYL ( RVYL ) was notified by NASDAQ that it has achieved the required shareholder equity threshold, thereby lifting the previous delisting risk, well ahead of anticipated merger between Roundtable and RYVYL ( RVYL ). Compliance confirmation followed...
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
Oct 15, 2025
Oct 15 (Reuters) - Danish drugmaker Novo Nordisk and Omeros ( OMER ) have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disorders, they said on Wednesday. As part of the agreement, Novo gains exclusive global rights to develop and commercialize Omeros' ( OMER...
Copyright 2023-2026 - www.financetom.com All Rights Reserved